Physician profile
Edwin G Olson
NPI 1730123647
$662.29
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $103 · 2021: $41.92.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $219.97 | 2019-2021 | |
| Abbott Laboratories | $88.84 | 2019-2021 | |
| Amarin Pharma, INC. | $65.73 | 2019 | |
| Amgen INC. | $58.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $44.62 | 2019 | |
| Boston Scientific Corporation | $36.22 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.77 | 2019 | |
| Medtronic Vascular, INC. | $33.55 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $31.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.22 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.68 | 2019 | |
| Chiesi USA, INC. | $13.51 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.